Multiple Myeloma

The AJMC^® Multiple Myeloma compendium is a comprehensive resource for clinical news and expert insights for this cancer.

EHA 2024: Highlights in Multiple Myeloma

Joseph Mikhael, MD, shares insights surrounding key updates in multiple myeloma management as presented at EHA 2024.

Visit Now

Latest News

July 2nd 2024

Advancements and Challenges in Treating Relapsed/Refractory Multiple Myeloma

By Brooke McCormick
Maggie L. Shaw

June 28th 2024

Ide-Cel Generates Durable Responses in Functionally High-Risk Myeloma

By Ariana Pelosci

June 27th 2024

The Tremendous Complexity of Treating RRMM

By Brooke McCormick
Maggie L. Shaw

June 21st 2024

Dr Suzanne Lentzsch Highlights Promising Linvoseltamab Results in Treating RRMM

By Brooke McCormick

June 13th 2024

MRD2STOP: Promise in Halting Myeloma Maintenance Therapy

By Maggie L. Shaw

Video Interviews

View All

July 7th 2024

Game-Changing Strategies for Early-Relapsed Myeloma

May 24th 2024

Future Indications and Frontline Potential of Cilta-Cel in Multiple Myeloma: Insights From Dr Binod Dhakal

May 6th 2024

Dr Binod Dhakal: The Importance of Patient Monitoring With Cilta-Cel Treatment

April 24th 2024

Dr Binod Dhakal Discusses Game-Changing Cilta-Cel Approval for RRMM

March 12th 2024

Dr Imran Khan Addresses Teclistamab’s Groundbreaking Impact and Ongoing Promise

March 4th 2024

Dr Imran Khan Presents a Closer Look at Teclistamab’s Weight-Based Dosing and Patient-Centric Approach

February 27th 2024

Dr Imran Khan Discusses Teclistamab’s Expanded Indication for RRMM

September 5th 2023

Dr Jordan Berlin Discusses Precision Medicine and Factoring Patient Preferences Into Treatment

August 28th 2023

Dr Joseph Mikhael on Strategies to Increase Diversity in Multiple Myeloma Trials

August 23rd 2023

Dr Joseph Mikhael: Researchers, Organizations Must Collaborate to Address Disparities in Multiple Myeloma

Continuing Medical Education

July 10th 2024

Recent Advances in BCMA-Directed Treatment in Multiple Myeloma: Insights and Application for Managed Care

1.0 Credits / Hematologic Cancer, Oncology

July 10th 2024

Keeping Pace With New Developments in Multiple Myeloma: Updates and Strategies to Optimize Bispecific Antibodies and CAR T-Cell Therapy

1.5 Credits / Oncology, Hematology, Hematologic Cancer

July 10th 2024

Addressing the Gaps and Clinical Challenges in Chronic Lymphocytic Leukemia: Updates and Strategies for Managed Care

1.5 Credits / Hematology, Hematologic Cancer, Oncology

Continuing Medical Education

View All

On-Demand Webinar

Recent Advances in BCMA-Directed Treatment in Multiple Myeloma: Insights and Application for Managed Care

1.0 Credits / Hematologic Cancer, Oncology

On-Demand Virtual Symposium

Keeping Pace With New Developments in Multiple Myeloma: Updates and Strategies to Optimize Bispecific Antibodies and CAR T-Cell Therapy

1.5 Credits / Oncology, Hematology, Hematologic Cancer

On-Demand Virtual Symposium

Addressing the Gaps and Clinical Challenges in Chronic Lymphocytic Leukemia: Updates and Strategies for Managed Care

1.5 Credits / Hematology, Hematologic Cancer, Oncology

More News

Sarclisa packaging | Image credit: Sanofi

June 4th 2024

IMROZ: Adding Isatuximab to SOC in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Cut Risk of Disease Progression or Death 40%

Mary Caffrey

Combining the anti-CD38 monoclonal antibody with a standard backbone triplet should be the new standard of care for newly diagnosed patients not eligible for transplant, said lead investigator Thierry Facon, MD.

Raymond Thertulien, MD, PhD | Image credit: LinkedIn

May 20th 2024

Raymond Thertulien, MD, PhD, on How Abnormalities Drive Treatment Choices in Multiple Myeloma

Rose McNulty

MM image | Image Credit: Svetlana-stock.adobe.com

May 15th 2024

CAR T Proves Effective and Safe for Refractory Multiple Myeloma

Maggie L. Shaw

Due to increasing reports of multiple myeloma and the emergence of chimeric antigen receptor (CAR) T-cell therapy as a treatment option, these investigators conducted a comprehensive review of the medical literature on the latest CAR T developments in the MM space.

Janssen image | Image Credit: Sundry Protography - stock.adobe.com

April 23rd 2024

Talquetamab Cost-Effective Breakthrough for RRMM

Maggie L. Shaw

The FDA granted accelerated approval to talquetamab on August 9, 2023, as a treatment option for adult patients with relapsed/refractory multiple myeloma (RRMM) who have failed at least 4 prior lines of therapy.

Open book on multiple myeloma | Image Credit: FelipeCaparros - stock.adobe.com.

April 11th 2024

Study Urges Personalized Care to Boost Quality of Life in Patients With MM

Maggie L. Shaw

Treatment and management of multiple myeloma (MM) is continuously evolving, and in this analysis, investigators discuss ever-present issues and potential solutions to optimize care for this patient population.

FDA approval indication | Image Credit: Dzmitry - stock.adobe.com

April 6th 2024

FDA Approves Cilta-Cel for Earlier Treatment of RRMM

Maggie L. Shaw

Most recently, the FDA’s Oncologic Drugs Advisory Committee unanimously voted to recommend ciltacabtagene autoleucel (Carvykti; Johnson & Johnson) in patients who have received at least 1 line of treatment for relapsed/refractory multiple myeloma (RRMM).

April 5th 2024

Ide-Cel Receives Approval for Earlier Treatment for Relapsed, Refractory Multiple Myeloma

Julia Bonavitacola

Idecabtagene vicleucel (ide-cel) was able to triple progression-free survival and reduce the risk of disease progression or death in a phase 3 trial.

Book of cases on multiple myeloma | Image Credit: FelipeCaparros - stock.adobe.com

March 27th 2024

Poor Well-Being Scores Linked to Early Treatment Stoppage in Multiple Myeloma

Maggie L. Shaw

Investigators used the Functional Assessment of Cancer Therapy-General General Physical Wellbeing Scale to collect data on patient-reported treatment-related adverse effects, to provide clinicians guidance on predicting risk of early treatment discontinuation among ECOG-ACRIN E1A11 trial participants.

Multiple Myeloma Diagram | Image Credit: fancytapis - stock.adobe.com

March 21st 2024

Fracture Risk Lowest for Alendronate, Pamidronate Use During MM Treatment

Maggie L. Shaw

In this analysis, 3 bisphosphonates (alendronate, pamidronate, and zoledronic acid) and 1 RANK ligand inhibitor (denosumab) were evaluated for their effectiveness at preventing osteoclasts from facilitating jaw degradation and reducing vertebral fracture risk among patients being treated for multiple myeloma.

enFuse injector | Image: Enable Injections

February 27th 2024

On-Body Delivery System enFuse Saves Time, Improves QOL for Patients

Mary Caffrey

An on-body delivery system approved last fall for paroxysmal nocturnal hemoglobinuria (PNH) has seen rapid uptake and is now being studied for use with isatuximab.

February 23rd 2024

Teclistamab Approved for Biweekly Dosing in R/R Multiple Myeloma

AJMC Staff

The bispecific antibody is used to treat patients with relapsed or refractory multiple myeloma (R/R MM) who have achieved and maintained a complete response for at least 6 months; this approval allows a dosing frequency of 1.5 mg/kg every 2 weeks.

Multiple myeloma diagnosis | Image credit: ibreakstock - stock.adobe.com

February 15th 2024

Daratumumab-Based Regimen Potential Promising Bridging Therapy for RRMM

Maggie L. Shaw

The combination of daratumumab and immumodulatory therapy was evaluated among patients with relapsed/refractory multiple myeloma (RRMM) who have failed prior treatment with immunomodulatory agents, proteasome inhibitors, and daratumumab as monotherapy or in combination.

Doctor is holding diagnosis Multiple myeloma | Image credit: Vitalii Vodolazskyi - stock.adobe.com.jpeg

February 7th 2024

Disability Degree, Home Health Use May Signal Need for Patient Support in MM

Maggie L. Shaw

Clinical investigators evaluated the impact of home health services on disability status and receipt of treatment among adults 66 years and older with a new diagnosis of multiple myeloma (MM).

multiple myeloma, text on white paper near stethoscope on blue background | Image credit: Svetlana stock.adobe.com.jpeg

January 29th 2024

Best Practices That Target Selinexor Treatment Improve MM-Related Outcomes

Maggie L. Shaw

Patient survival and such treatment-related outcomes as time to treatment failure and treatment duration improved following implementation of a best practices program that focused on selinexor administration for multiple myeloma (MM), with implications for other anticancer medications.

Health Disparities Poster | image credit: Colored Lights - stock.adobe.com

January 26th 2024

Racial Disparities Persist in Multiple Myeloma Treatment

Kyle Munz

A claims-based study analyzing Medicare beneficiaries with multiple myeloma found that racial disparities still impact treatment in this patient population.

January 20th 2024

Overcoming Barriers to Care Equity in Multiple Myeloma

Rose McNulty

January 19th 2024

Additional Analyses Needed to Optimize Treatment Efficacy, Sequencing in MM

Maggie L. Shaw

This literature review investigated outcomes related to relapsed/refractory multiple myeloma (MM) among patients 65 years and older.

Managing finances in health care | Image Credit: janews094 - stock.adobe.com

January 13th 2024

New Research Further Supports Use of Financial Navigators in Myeloma Care

Kristie L. Kahl

Patients with multiple myeloma are living longer; therefore, their lifelong treatment expenses can become burdensome.

Doctor with patient in medical office | Image Credit: sebra - stock.adobe.com

January 4th 2024

Understanding the Patient Experience With Belantamab Mafodotin for RRMM

Maggie L. Shaw

A qualitative interview study gauged patients’ experiences with belantamab mafodotin, which is used to treat relapsed/refractory multiple myeloma (RRMM) following failure on at least 4 prior therapies.

Alissa Visram, MD | Image credit: Ottawa Hospital Research Institute

December 27th 2023

Study Finds Huge Gap Between Clinical Trial Data and Real-World Outcomes in Multiple Myeloma

Mary Caffrey

Real-world patients were on average older and had more comorbidities than those in clinical trials, factors previously seen in comparisons between patients in clinical trials and real-world settings.

December 26th 2023

ICYMI: Highlights From EHA 2023

Rose McNulty

The most-read articles from the 2023 European Hematology Association (EHA) Annual Meeting covered the most up-to-date treatment strategies for hematological malignancies, racial disparities in treatment patterns for blood cancers, and updates on immunotherapy as a tool in hematologic oncology.

L. Andres Sirulnik, MD, PhD | Image credit: Regeneron

December 22nd 2023

LINKER-MM1: Updated Data Show 46% Complete Responses to Linvoseltamab at 11 Months in R/R Multiple Myeloma

Mary Caffrey

Regeneron officials say they are on track to file for FDA approval for the bispecific antibody by the end of 2023.

Multiple myeloma | Image credit: David Litman - stock.adobe.com

December 20th 2023

Older, Younger Patients With MM Show Similar Outcomes With Teclistamab

Rose McNulty

Real-world data presented at the 2023 American Society of Hematology Annual Meeting and Exposition showed similar toxicity profiles and outcomes among older and younger patients with multiple myeloma (MM) treated with teclistamab.

December 19th 2023

From CAR T’s “Wait List Mortality” to “Tethering” Bispecific Antibodies, Oncologists Navigate Time-Sensitive Sequencing in Multiple Myeloma

Ryan Flinn

December 19th 2023

Top 5 Most-Read Multiple Myeloma Articles of 2023

Rose McNulty

Our top multiple myeloma (MM) content this year included research suggesting many patients still face poor prognoses despite advances, a case study of unique MM presentation, and research presented at the 2022 American Society of Hematology Annual Meeting.

Blood cells flowing | Image credit: Катерина Євтехова - stock.adobe.com

December 16th 2023

Talquetamab Dose Modifications May Lower AEs While Maintaining Efficacy in R/R Multiple Myeloma

Silas Inman

Dose modifications of talquetamab improved on-target adverse effects while maintaining responses for patients with relapsed/refractory multiple myeloma.

Illustration of T cells - Sebastian - stock.adobe.com

December 15th 2023

Patients With Multiple Myeloma Lack Awareness of CAR T-Cell Therapy, Research Says

Giuliana Grossi

The results indicated that a substantial proportion of patients, particularly in rural, less educated, and elderly demographics, are insufficiently informed about novel MM treatments, including chimeric antigen receptor (CAR) T-cell therapies and bispecific antibody alternatives.

Cardiovascular system | Image credit: appledesign - stock.adobe.com

December 8th 2023

Real-World Data Show Poor Outcomes Among Patients With ACS and Blood Cancers

Sabrina Serani

A real-world analysis found that patients with acute coronary syndrome who were also diagnosed with a hematologic malignancy had worse survival outcomes, and patients with multiple myeloma were overrepresented in the population.

Blood Cells | Image credit: Катерина Євтехова - stock.adobe.com

November 30th 2023

Study Finds ASCT Similarly Safe, Effective in Older and Younger Patients With Multiple Myeloma

Rose McNulty

A real-world study suggests high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is feasible for appropriately selected elderly patients, with similar results seen in older and younger patients.

Multiple myeloma blood testing | Image credit: luchschenF - stock.adobe.com

November 29th 2023

Belantamab Mafodotin Improves PFS in Relapsed/Refractory Multiple Myeloma

Hayley Virgil

Second-line treatment with belantamab mafodotin plus bortezomib/dexamethasone in patients with relapsed/refractory multiple myeloma is supported by findings from the phase 3 DREAMM-7 study.

1 2 3 4 5 6 7 8

...

9 >